ARGX Argenx: Multiplikator Forward P/S
argenx SE is mitigating risks by developing therapies for a wide range of severe autoimmune pathologies. The forward P/S multiple reflects current market expectations, with the parameter set at 8.60. Growth is accelerating through partnerships with research centers and biopharmaceutical firms to launch new antibodies. Meanwhile, contractor production capacities are operating at peak efficiency, undergoing scheduled modernization without downtime.
ARGX (argenx BVBA): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Total Utang marang Modal argenx SE|ARGX - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas argenx SE|ARGX - Utang agregat perusahaan|Utang marang nilai buku argenx BVBA|ARGX - Tanggungan utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan argenx|Likuiditas cepet argenx.com
- data bathi bisnis lan rasio investasi:
ARGX - Asil keuangan resik|Proyeksi bathi mangsa ngarep argenx SE|ARGX - Kapitalisasi marang bathi|Pangali Forward P/E Argenx|ARGX - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan argenx BVBA|ARGX - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) argenx|ARGX - Bathi resik saben saham sajroning taun lumaku|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan argenx.com|ARGX - Wutah bathi saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep argenx SE
- statistik dodolan lan pendapatan perusahaan:
Pambiji fundamental perusahaan:argenx (ARGX)
The specifics of developing immunological drugs involving multi-year investments make the forward P/S ratio a key indicator for valuing the future monopoly of argenx SE (ARGX). This metric measures the risk of a valuation correction if financial targets are not met, where inflated values signal that the asset is overbought. The calculation is based on discounting expected revenue to the cost of capital, allowing the investor to determine the extent of market expectations currently priced in.
Analisis pesaing argenx SE
Multiplikator Forward P/S BNTX (BioNTech)|Abivax Pharma (ABVX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ADMA Bio - Multiplikator Forward P/S|PTGX - Multiplikator Forward P/S|Immunovant, Inc. (IMVT) - Rasio rega marang prakiraan pendapatan|kiniksa.com - Rega forward marang dodolan|GRFS (Grifols) - Multiplikator Forward P/S|ADPT - Prakiraan rega marang pendapatan|Multiplikator Forward P/S CLDX|AUPH - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan BioCryst BCRX|VERA: Kapitalisasi marang prakiraan pendapatan|DNTH: Multiplikator forward rega marang pendapatan|PHVS (Pharvaris NV) - Kapitalisasi marang prakiraan pendapatan|ABCL (AbCellera Biologics Inc) - Multiplikator forward rega marang pendapatan|Tourmaline - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Precigen, Inc.|pharming.com (PHAR) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S NKTR|UPB - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S ZBIO (Zenas Biopharma, Inc.)|Multiplikator Forward P/S Immunome Bio IMNM|GOSS - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan KALV (kalvista.com)|SEPN: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Pieris Pharma PVLA|Multiplikator forward rega marang pendapatan SVRA|Kapitalisasi marang prakiraan pendapatan RIGL (Rigel Corp)|Rasio rega marang prakiraan pendapatan AnaptysBio, Inc. (ANAB)|ATXS: Rega mangsa ngarep marang pendapatan|Multiplikator Forward P/S ENGN (enGene)|Rega forward marang dodolan RAPT|Aerovate - Multiplikator Forward P/S|ACRS - Multiplikator Forward P/S|Kyverna Therapeutics (KYTX) - Rasio rega marang prakiraan pendapatan|tizianalifesciences.com - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Cabaletta Bio|Multiplikator forward rega marang pendapatan Ventyx Biosciences Inc. (VTYX)|Multiplikator Forward P/S THTX|Multiplikator Forward P/S Avalo Therapeutics Inc (AVTX)|Eledon Pharmaceuticals - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan AGEN|Climb Bio - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Zura Bio Ltd ZURA|aTyr (ATYR) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Adagene Inc.|Rasio rega marang prakiraan pendapatan ImageneBio|Multiplikator forward rega marang pendapatan Shattuck Therapeutics (STTK)|Multiplikator forward rega marang pendapatan EQ (Equillium, Inc.)|Multiplikator Forward P/S connectbiopharm.com (CNTB)|Rasio rega marang prakiraan pendapatan Immunic IMUX|ATRA: Kapitalisasi marang prakiraan pendapatan|InflaRx GmbH - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep x4pharma.com|ACET: Multiplikator Forward P/S|Celularity (CELU) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan INmune Bio Corp|BRNS: Rega forward marang dodolan|Multiplikator Forward P/S KZR|sabbiotherapeutics.com (SABS) - Prakiraan rega marang pendapatan|Multiplikator Forward P/S AKTX (Akari Therapeutics Plc)|Enlivex Therapeutics Ltd (ENLV) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|QTTB - Rasio rega marang prakiraan pendapatan|GOVX (GeoVax Corp) - Kapitalisasi marang prakiraan pendapatan|EDSA (Edesa Biotech, Inc.) - Multiplikator forward rega marang pendapatan|Kapitalisasi marang prakiraan pendapatan IBIO|Multiplikator forward rega marang pendapatan CARM|XTLB: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Bolt Biotherapeutics (BOLT)|Rasio kapitalisasi marang dodolan sing dikarepake hcwbiologics.com|Multiplikator Forward P/S APVO (Aptevo Therapeutics Inc.)|AIM ImmunoTech, Inc. (AIM) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Aditxt Corp - Multiplikator Forward P/S|GRI - Multiplikator Forward P/S|XORTX (XRTX) - Rasio rega marang prakiraan pendapatan|Vyome Therapeutics - Rega forward marang dodolan|REVB (Revelation Biosciences) - Multiplikator Forward P/S|INDP - Prakiraan rega marang pendapatan|Multiplikator forward rega marang pendapatan SCNI (Scinai Immunotherapeutics Ltd.)|calcimedica.com - Kapitalisasi marang prakiraan pendapatan|Rasio rega marang prakiraan pendapatan Affimed N.V. AFMD|ALLK (Allakos Inc) - Rega mangsa ngarep marang pendapatan|HOOKIPA - Multiplikator Forward P/S|Rega forward marang dodolan IGMS (IGM Biosciences, Inc.)|ITOS: Multiplikator Forward P/S|Ocean Biomedical Inc (OCEA) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan TC BioPharm (Holdings) PLC|THRD: Rega forward marang dodolan
